Connect Biopharma Holdings Ltd. (CNTB) has released an update.
Connect Biopharma Holdings Ltd. has reported a successful 2023 with two positive trial readouts for their lead drug, rademikibart, showing promise in treating asthma and atopic dermatitis. The company is preparing for pivotal meetings with the FDA in Q2 2024 and has secured an exclusive licensing agreement with Simcere for the drug’s commercialization in Greater China. Furthermore, with a strong financial position, Connect Biopharma anticipates its current cash reserves will fund operations well into 2026.
For further insights into CNTB stock, check out TipRanks’ Stock Analysis page.
